Dan Hinmon, MCSMN Director

Posts: 2878
Joined: Apr 13, 2011

The Cost of Drugs for Rare Diseases Is Threatening the U.S. Health Car

Posted by @DanHinmon, Apr 7, 2017

This opinion piece by the University of Utah School of Medicine vice chair of research is sobering – even depressing.

Can our health care system afford the cost of a life-saving drug for spinal muscular atrophy (SMA) that costs $750,000 per patient in the first year? That’s just one example.

Here’s another: “Consider the two drugs for treating Duchenne muscular dystrophy that the FDA approved in the last six months: eteplirsen, which is sold by Sarepta Therapeutics and costs $300,000 annually per patient, and deflazacort, which is sold by Marathon Pharmaceuticals and costs $89,000 annually per patient… Approval of such costly drugs exposes an uncomfortable truth: scientific discovery has outpaced health care economics.”


Please login or register to post a reply.

© Mayo Clinic Social Media Network. All Rights Reserved.